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Aims: Metformin is an insulin sensitizing agent with beneﬁcial effects in diabetic patients on glycemic levels
and in the cardiovascular system. We examined whether the metabolic changes and the vascular dysfunction
in monosodium glutamate-induced obese non-diabetic (MSG) rats might be improved by metformin.
Main methods: 16 week-old MSG rats were treated with metformin for 15 days and compared with age-
matched untreated MSG and non-obese non-diabetic rats (control). Blood pressure, insulin sensitivity, vascu-
lar reactivity and prostanoid release in the perfused mesenteric arteriolar bed as well as nitric oxide produc-
tion and reactive oxygen species generation in isolated mesenteric arteries were analyzed.
Key ﬁndings: 18-week-old MSG rats displayed higher Lee index, fat accumulation, dyslipidemia, insulin resis-
tance and hyperinsulinemia. Metformin treatment improved these alterations. The norepinephrine-induced
response, increased in the mesenteric arteriolar bed from MSG rats, was corrected by metformin. Indometh-
acin corrected the enhanced contractile response in MSG rats but did not affect metformin effects. The sen-
sitivity to acetylcholine, reduced in MSG rats, was also corrected by metformin. Indomethacin corrected
the reduced sensitivity to acetylcholine in MSG rats but did not affect metformin effects. The sensitivity to
sodium nitroprusside was increased in preparations from metformin-treated rats. Metformin treatment re-
stored both the reduced PGI2/TXA2 ratio and the increased reactive oxygen species generation in prepara-
tions from MSG rats.
Signiﬁcance: Metformin improved the vascular function in MSG rats through reduction in reactive oxygen
species generation, modulation of membrane hyperpolarization, correction of the unbalanced prostanoids re-
lease and increase in the sensitivity of the smooth muscle to nitric oxide.© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Obesity represents a major public health problem (Hill, 2006).
This condition is associated with increased risk of type 2 diabetes
(Goran et al., 2003). Epidemiological and observational studies
have shown that overweight/obese individuals tend to be insulin
resistant and become more insulin sensitive with weight loss
(Lionetti et al., 2009). These ﬁndings suggest that insulin resistance
is the link between obesity and the related clinical syndromes, such
as type 2 diabetes.
Obesity is associated with endothelial dysfunction (Stapleton et
al., 2008), which in turn can be considered the ﬁrst step in the pro-
gression of cardiovascular diseases (Lerman and Zeiher, 2005). Agy, Institute of Biomedical Sci-
Brazil. Tel./fax: +55 11 3091
vier OA license.number of experimental and clinical studies have consistently dem-
onstrated impaired arterial function manifested by reduced
endothelium-dependent vasodilatation in obesity (Tziomalos et al.,
2010; Lobato et al., 2010; Zalesin et al., 2008). We have previously
demonstrated that obesity induced by monosodium glutamate
(MSG) impairs microvascular reactivity in rats. An altered ability of
the endothelium to maintain the vascular homeostasis through the
release of endothelium-derived relaxing factors (EDRFs) and
endothelium-derived contracting factors (EDCFs) was demonstrated
in MSG-induced obese rats (Lobato et al., 2010).
The biguanide metformin (dimethylguanidine) is one of the most
commonly used drugs for type 2 diabetes treatment (Nathan et al.,
2006). There are evidences for a potential role of metformin in the
prevention of type 2 diabetes in obese patients (Diabetes Prevention
Program Research Group, 2002). Metformin has also been associated
with reduction in the progression of the cardiovascular repercussions
of obesity (UKPDS, 1998; Kurukulasuriya et al., 1999; Grant, 2003).
Therefore, we hypothesized that metformin could have beneﬁcial
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ence of a diabetic condition. Considering that obesity and insulin re-
sistance impair the vascular function before the onset of type 2
diabetes (Goran et al., 2003; Lobato et al., 2010), the aim of the pre-
sent study was to investigate the effects of metformin on metabolic
and vascular alterations in obesity. We used non-diabetic MSG
obese rats, that manifests obesity and vascular dysfunction (Lobato
et al., 2010), providing a suitable model to investigate the effects of
metformin in obesity before the onset of diabetes.
Methods
Animals
The investigation was approved by the Ethical Committee for An-
imal Research of the Institute of Biomedical Sciences, University of
Sao Paulo (Protocol no. 007/04), conformed to the Guide for the Care
and Use of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1996). Male Wistar
rats received subcutaneous injections of MSG [4.0 g/kg body weight;
Sigma-Aldrich, Germany] dissolved in 0.9% NaCl (MSG rats) or an
equivalent volume of vehicle (control rats), from the second to the
sixth day after birth. The breeding conditions were followed as previ-
ously described (Akamine et al., 2006).
After 16 weeks, rats from the MSG group were divided into two
subgroups: 1 — rats from this subgroup received a daily dose of met-
formin (300 mg/kg, for 15 days), by gavage; 2 — rats from this sub-
group received the same volume of vehicle (water) by the same
route and for the same period, and will be identiﬁed as MSG rats.
All experimental groups were studied at 18 weeks of age.
Assessment of water and food consumption was performed by
placing the animals in metabolic cages. Rats were acclimated for
72 h and data were collected over the next 24 h.
Blood pressure — tail-cuff method
Blood pressure (BP) was measured in unanesthetized animals by
an indirect tail-cuff method (PowerLab 4/S, ADInstruments, Austra-
lia). Rats were maintained at 37 °C for 10 min, and then three consec-
utive stable measurements were averaged.
Intravenous insulin tolerance test
Tail blood samples were collected before (0 min) and 4, 8, 12 and
16 min after an intravenous injection of regular insulin (0.75 U/kg
b.w., Biobras, Brazil). The constant rate for blood glucose disappear-
ance during the Insulin Tolerance Test (kITT) was calculated based
on the linear regression of the neperian logarithm of blood glucose
concentrations obtained during the test.
Blood biochemical assays
For biochemical assays, rats were submitted to food deprivation
(5 h) and weighted. After sodium thiopental (50 mg/kg, intraperito-
neally, Cristália, Brazil) anesthesia and laparotomy, blood samples
were taken from the descending aorta. Glucose levels and the lipid
proﬁle were assessed spectrophotometrically using colorimetric
method (Celm, Brazil). Insulin was determined using radioimmuno-
assay (Linco, USA). The Homeostasis Model Assessment (HOMA-IR),
an index of insulin resistance (Matsuda, 2010), was calculated from
glucose and insulin levels, using the equation: HOMA-IR=fasting in-
sulin (in μU/mL)×fasting glucose (in mmol/L)/22.5. The Lee's obesity
index was calculated as follows: body weight1/3(g)/nasal-anal length
(cm)×100. Visceral adipose tissue (periepididymal and retroperito-
neal) and the lean mass (soleus and extensor digitorum longus)were removed from each animal. The tissues were weighted after dis-
section and separation from vessels and other connective tissues.
Vascular reactivity in the perfused mesenteric arteriolar bed
The perfused mesenteric arteriolar bed was prepared as previous-
ly described (Lobato et al., 2010). Under anesthesia, the abdominal
cavity was opened and a polyethylene cannula was inserted into the
superior mesenteric artery. The whole preparation was cut close to
the intestinal border and transferred to an organ bath at 37 °C and
perfused at a constant ﬂow rate (2 mL/min) by a peristaltic pump
with Krebs–Henseleit solution (pH 7.4) containing 5% CO2 and 95%
O2. The composition of the solution was (in mM): NaCl 130.0, KCl
4.7, CaCl2 1.6, NaHCO3 14.9, MgSO4 1.17, KH2PO4 1.18, EDTA disodium
salt 0.026 and glucose 5.5. Vascular responses were evaluated as
changes in the perfusion pressure, measured with a pressure trans-
ducer (BP Transducer, ADInstruments, Australia) and recorded on a
digital acquisition system (Power Lab, ADInstruments).
After a 45-min equilibration period, concentration–effect curves
to norepinephrine (NE, 0.1–100 μM), potassium chloride (KCl,
5–225 mM), a direct acting smooth muscle contracting agent, acetyl-
choline (ACh, 0.001–30 μM), an endothelium-dependent vasodilator,
and sodium nitroprusside (SNP, 0.001–10 μM), a NO donor, were
obtained. All curves were performed in the presence of desipramine
(inhibitor of NE uptake, 10 nM). The vasodilator responses to ACh
and SNP were determined in NE-contracted preparations in a concen-
tration that produced 80% of the maximal contractile response.
In order to determine the role of NO, prostanoids and EDHF on the
NE and ACh responses, Nω-Nitro-L-arginine Methyl Ester (L-NAME,
100 μM), a NO synthase inhibitor, indomethacin (10 μM), a cyclooxy-
genase (COX) inhibitor, or tetraethylammonium (TEA, 2 mM), a non-
selective K+-channel blocker, were used. Each drug was added to the
perfusing solution 30 min before the concentration–effect curves
were performed and was maintained throughout the experiment.
The concentrations of the agents used were based on the data in the
literature (Lobato et al., 2010).
Prostanoid release measurements
The isolated mesenteric arteriolar bed was allowed to equilibrate
for 30 min. The ability of the preparations to release TXA2 (estimat-
ed from measurements of 11-dehydro-TXB2) and PGI2 (estimated
from measurements of 6-keto-PGF1α) was assessed in 1 mL samples
of perfusate collected before and after stimulation with NE
(100 nM) or ACh (30 nM) using enzyme immunoassay kits (Cayman
Chemical, USA).
Measurement of nitric oxide production in mesenteric arteries
Nitric oxide (NO) production was determined using 4,5-diamino-
ﬂuorescein diacetate (DAF-2), a NO-sensitive ﬂuorescent dye (Lobato
et al., 2010). Mesenteric arteries were dissected, embedded in a freez-
ing medium and frozen. Transverse arteriolar cryostat sections
(20 μm) were collected on glass slides and incubated at 37 °C with
8 μM DAF-2 in phosphate buffer (0.1 M, pH 7.4) containing CaCl2
(0.45 mM). After 30 min, the sections were stimulated with ACh
(100 μM) in the absence/presence of BH4 (1 μM). Digital images
were collected on a microscope (Carl Zeiss, Germany) equipped for
epiﬂuorescence and with a ﬂuorescein ﬁlter. The images were ana-
lyzed with the Image software (KS-300, Zeiss) by measuring the
mean optical density of the ﬂuorescence in the endothelium.
Reactive oxygen species generation in mesenteric arteries
Reactive oxygen species (ROS) generation was determined by
hydroethidine (Lobato et al., 2010). Transverse mesenteric arteries
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incubated at 37 °C with hydroethidine (2.5 μM) in phosphate buffer
(0.1 M, pH 7.4). Images were collected on a microscope equipped
for epiﬂuorescence and with a rhodamine ﬁlter. The mean optical
density of the ﬂuorescence in the vessel wall was measured. To eval-
uate superoxide (O2−) production and the participation of NOS in
the ROS generation, mesenteric arteries were treated with SOD
(150 IU/mL) or L-NAME (100 μM), respectively, 30 min before the tis-
sues were frozen.
Drugs
Metformin (Glifage®) was purchased from Merck (Rio de Janeiro,
Brazil); MSG, NE, ACh, desipramine, sodium nitroprusside, indometh-
acin, L-NAME, SOD and TEA were purchased from Sigma Chemical
(USA); Hydroethidine was purchased from Polysciences (USA) and
DAF-2 was purchased from Alexis (USA).
Data analyses
Contraction is expressed as the KCl- and NE-induced perfusion
pressure subtracted from the baseline pressure, and vasodilatation
is represented as a percentage of the maximal response to NE. pD2
(− log EC50) and the maximum response (RMAX) were calculated by
non-linear regression analysis. Data are represented as mean±SEM
and compared by one-way ANOVA. p Values less than 0.05 were con-
sidered signiﬁcant.
Results
General characteristics of metformin-treated rats
General and biochemical characteristics of the different groups
are presented in Table 1. The food intake was not different among
groups. The higher Lee index and fat mass weight found in MSG
rats were signiﬁcantly reduced by metformin treatment. The lean
mass weight of metformin-treated MSG rats was not different from
that of control rats or from MSG rats. The levels of cholesterol,Table 1
General characteristics of monosodium glutamate-induced obese rats subjected to
metformin treatment.
Parameter Control (n=10) MSG (n=10) MSG-MET (n=10)
Lee index (×100) 29.5±0.15 31.1±0.22⁎ 30.2±0.15⁎,#
Retroperitoneal
WAT (g/100 g)
1.0±0.07 3.0±0.1⁎ 2.1±0.1⁎,#
Periepididymal
WAT (g/100 g)
1.2 ±0.04 2.8±0.1⁎ 1.9±0.08⁎,#
Soleus muscle (g/100 g) 0.04±0.001 0.04±0.001 0.04±0.001
EDL muscle (g/100 g) 0.04±0.001 0.03±0.002 0.04±0.001
Food intake (g/100 g/day) 6.1±0.2 6.3±0.2 6.18±0.1
Water intake
(mL/100 g/day)
8.1±0.1 8.3±0.1 8.3±0.2
Total cholesterol (mg/dL) 74.8±4.2 108.7±8.0⁎ 59.8±3.1#
Triacylglycerols (mg/dL) 40.7±8.0 124.7±9.9⁎ 68.6±10.0#
LDL-cholesterol (mg/dL) 48.5±2.9 78.0±4.6⁎ 50.6±6.1#
VLDL-cholesterol (mg/dL) 7.6±1.5 24.4±2.0⁎ 10.6±2.6#
HDL-cholesterol (mg/dL) 43.4±1.9 18.5±2.1⁎ 53.5±3.1⁎,#
Glucose (mg/dL) 121.0±3.2 120.1±5.5 118.1±2.8
Insulin (ng/mL) 2.5±0.2 5.9±0.4⁎ 3.0±0.2#
kITT (%/min) 3.9±0.20 2.3±0.1⁎ 4.1±0.09⁎,#
HOMA-IR index 15.5±1.5 36.2±2.6⁎ 17.9±1.3⁎,#
Blood pressure (mm Hg) 115.5±1.8 122.3±2.3 117.9±1.6
Values are mean±SEM; WAT, white adipose tissue; EDL, extensor digitorum longus;
LDL, low density lipoprotein; kITT, constant rate for blood glucose disappearance;
HOMA-IR, homeostasis model assessment-insulin resistance; n, number of animals tested.
⁎ pb0.05 vs. control.
# pb0.05 vs. MSG.triglycerides and low density lipoprotein (LDL) cholesterol, increased
in MSG rats, were restored to the control levels after metformin
treatment. In addition, metformin treatment promoted increase in
high density lipoprotein (HDL) cholesterol, restoring the levels of
this lipoprotein to values observed in control rats. Although similar
serum glucose levels were found among groups, MSG rats displayed
enhanced HOMA-IR index, and hyperinsulinemia. Metformin treat-
ment restored these parameters to values observed in control rats.
No difference in BP levels was found among groups.
Vascular reactivity in the mesenteric arteriolar bed
Similar basal perfusion pressure was found in preparations from
all experimental groups (around 20 mm Hg). Metformin treatment
did not alter the contractile response induced by KCl (in mm Hg, con-
trol=75.2±4.1, MSG=76.2±5.7, MSG-Met=78.6±6.1). However,
the vasoconstrictor response to NE, signiﬁcantly increased in MSG
rats, was corrected bymetformin (Fig. 1A). Perfusion of the mesenter-
ic arteriolar bed with Krebs–Henseleit solution containing L-NAME or
TEA for 30 min further increased the response to NE in all experimen-
tal groups (Fig. 1B and C). Indomethacin corrected the enhanced con-
tractile response to NE inMSG rats. The effect of metformin correcting
the enhanced contractile response observed in MSG rats was not al-
tered by indomethacin (Fig. 1D).
Metformin treatment restored the reduced sensitivity (lower
pD2) to ACh observed in the mesenteric arteriolar bed from MSG
rats. Perfusion of the preparations with L-NAME decreased the max-
imum response to ACh in all experimental groups (Fig. 2B). Perfu-
sion with TEA decreased signiﬁcantly the maximal vasodilator
response to ACh in MSG rats. On the other hand, in preparations
from metformin-treated rats, similar to that observed in control
rats, TEA did not reduce the response to ACh (Fig. 2C). The sensitiv-
ity to ACh in the mesenteric arteriolar bed from control rats was not
modiﬁed by indomethacin (pD2, control=7.7±0.1, Control+
Indo=7.6±0.2, Fig. 2D), however, in MSG rats this agent was able
to correct the reduced sensitivity to ACh (MSG=7.0±0.1, MSG+
Indo=7.8±0.05, pb0.05 vs. respective group in the absence of the
inhibitor, Fig. 2D). In preparations from metformin-treated rats,
similar to that observed in control rats, the response to ACh was
not affected by perfusion with indomethacin (MSG-MET=7.6±0.1,
MET+Indo=7.9±0.1, Fig. 2D).
The mesenteric arteriolar bed from metformin-treated rats
was more sensitive (lower EC50, represented by pD2 values)
to SNP when compared to both MSG and control preparations
(pD2, control=6.6±0.1, MSG=6.5±0.2, MSG-MET=7.1±0.1,
pb0.05, Fig. 2E).
Prostanoid release from the mesenteric arteriolar bed
Metformin treatment restored the reduced PGI2/TXA2 ratio ob-
served in unstimulated, NE- and ACh-stimulated preparations from
MSG rats (Fig. 3).
Measurement of nitric oxide production in mesenteric arteries
The reduced basal and ACh-stimulated NO production found in ar-
teries from MSG rats was not affected by metformin treatment
(Fig. 4). The addition of exogenous BH4, an NO synthase cofactor
that enhances NO production or L-NAME, an NO synthase inhibitor,
to preparations from MSG rats and MSG-MET rats stimulated with
ACh, fully corrected NO production (Fig. 4).
Superoxide anion generation in mesenteric arteries
The increased ROS generation observed in mesenteric arteries
fromMSG rats was corrected by metformin treatment. The incubation
Fig. 1. Concentration–response curves to norepinephrine in mesenteric arteriolar beds from control, monosodium glutamate-induced obese rats (MSG) and metformin-treated
MSG rats (MSG-MET) in the absence (A) or presence of L-NAME (B, 100 μM), TEA (C, 2 mM) or indomethacin (D, Indo 10 μM). * pb0.05 vs. control. # pb0.05 vs. respective
group in the absence of blockade. Perfusion pressure increase is presented as the mean±S.E.M of eight independent experiments.
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values similar to those obtained in MSG-MET rats (Fig. 5).
Discussion
In the present study we demonstrated that metformin had beneﬁ-
cial effects in non-diabetic MSG rats correcting the insulin resistance,
the hyperinsulinemia and the altered lipid proﬁle. We also demon-
strated that metformin treatment was associated with reduction in
Lee Index as well as in visceral fat accumulation. Previous studies per-
formed in both humans or in experimental models of type 2 diabetes
have demonstrated improvement of metabolic parameters as well as
reduction in body weight after metformin treatment (Diabetes
Prevention Program Research Group, 2002; UKPDS, 1998; Hundal et
al., 2000), reinforcing the potential role of this drug as an early ther-
apeutic intervention to prevent the development of the comorbidities
associated with type 2 diabetes.
Oral treatment with metformin led to a decrease in Lee index, an
accurate Index that correlates highly with body fat. This effect is not
related to the food intake since we did not observe difference in this
parameter among groups. Metformin is widely recognized to have ei-
ther little effect on body weight or to facilitate modest weight loss in
type 2 diabetic patients (UKPDS, 1998; Hundal et al., 2000). Similarly,
metformin has shown to induce weight loss in obese non-diabetic in-
dividuals (Nichols and Gomez-Caminero, 2007; Glueck et al., 2001),
although long duration studies in this population are scarce. The
weight loss by metformin treatment in diabetic patients has been re-
lated to reduction in fat mass (Kurukulasuriya et al., 1999). Accord-
ingly, we observed that metformin treatment was able to reduce the
fat accumulation observed in MSG rats along with reduction in the
Lee Index, an accurate index that determines the body mass gain cor-
rected by the length.
Metformin had also advantageous effects on lipid proﬁle besides its
effects on whole-body insulin sensitivity in MSG rats. In type 2 diabet-
ic patients the correction of the dyslipidemia after metformin treat-
ment has been associated with decreased synthesis and increasedclearance of VLDL. This may provide an indirect mechanism by
which metformin improves the metabolic changes in these patients
as described by Wiernsperger and Bailey (1999). Considering that fat
accumulation can contribute to changes of lipid proﬁle in obesity by
increasing the release of free fatty acids (FFAs), the effect ofmetformin
reducing visceral fat and its insulin sensitizer effect in MSG rats might
contribute to the correction of the dyslipidemia observed. Another no-
table effect of metformin was the increase in HDL cholesterol levels in
MSG rats. Even in patients, it has been shown that metformin in-
creases HDL cholesterol levels in overweight, diet-controlled type 2
diabetic patients (Lawrence et al., 2004). Low fasting plasma HDL cho-
lesterol has been reported to be associated with insulin resistance
(Abbasi et al., 1999). Based on this, the correction of the insulin resis-
tance after metformin treatment might also be involved in the in-
crease of HDL cholesterol in MSG rats.
A substantial amount of evidence has consistently demonstrated
that obesity is closely related to impaired endothelial function either
in animals (Lobato et al., 2010), or in patients (Stapleton et al., 2008;
Lerman and Zeiher, 2005; Tziomalos et al., 2010). Considering that
metformin has beneﬁcial effects on vascular function in type 2 diabe-
tes (Bailey, 2008), we evaluated in metformin-treated MSG rats, the
endothelium-dependent vasodilator response, tested with ACh, and
the vasoconstriction induced by NE, that has its response negatively
modulated by the endothelium. In fact, metformin promoted beneﬁ-
cial effects in MSG rats correcting the increased response to NE and
the lower response to ACh observed in the mesenteric arteriolar bed.
Endothelial dysfunction is usually associated with reduction in NO
production and/or increase in NO metabolism (Feletou and
Vanhoutte, 2006). It has been suggested that the vasculoprotective ef-
fects of metformin are mainly due to improvement of NO signaling
(Bailey, 2008). Interestingly, an important ﬁnding in our study was
that the correction of the endothelial dysfunction with metformin
treatment in MSG rats is not due to improvements in NO signaling.
This is supported by the fact that metformin did not correct the re-
duced endothelium-dependent NO production in mesenteric arteries
from MSG rats.
Fig. 2. Concentration–response curves to acetylcholine in mesenteric arteriolar beds from control, monosodium glutamate-induced obese rats (MSG) and metformin-treated MSG
rats (MSG-MET) in the absence (A) or presence of L-NAME (B, 100 μM), TEA (C, 2 mM) or indomethacin (D, Indo 10 μM). E — concentration–response curves to sodium nitroprus-
side in mesenteric arteriolar beds from control, monosodium glutamate-induced obese rats (MSG) and metformin-treated MSG rats. * pb0.05 vs. control. # pb0.05 vs. respective
group in the absence of blockade. Relaxation (measured by percentage of contraction reduction) is presented as the mean±S.E.M of eight independent experiments.
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uncoupling, a process in which eNOS generates O2− instead of NO
when the concentrations of either L-arginine, the substrate of NOS,
or tetrahydrobiopterin (BH4), a cofactor of the enzyme, are depleted,
may mediate decrease in NO bioavailability (Förstermann and
Münzel, 2006). O2− generation can be involved in the reduction of
endothelium-dependent vasodilatation, by impairing NO bioavail-
ability (Hopps et al., 2010). We have previously demonstrated uncou-
pling of eNOS in mesenteric arteries from 16-week-old MSG rats
(Lobato et al., 2010). In 18-week-old MSG rats, incubation of mesen-
teric arteries with BH4 corrected the reduced NO production. Further-
more, the treatment of these arteries with either SOD, an O2−
scavenger or L-NAME, a NOS inhibitor, reduced ROS generation, con-
ﬁrming the role of eNOS as a source of O2− production. Interestingly,
although metformin did not correct the reduced NO production in
MSG rats, it exerted an antioxidant effect by decreasing the O2− pro-
duction. Taking the above ﬁndings together, we speculate that met-
formin's beneﬁcial effects on endothelial dysfunction in MSG rats
may be at least partly due to the suppression of the oxidative stress.
The antioxidant effect of metformin has been demonstrated inprevious studies (Gallo et al., 2005; Mahrouf et al., 2006; Ouslimani
et al., 2005); however, the role of it on the beneﬁcial effects of metfor-
min in obesity has not been described before.
In the present study, an additional mechanism involved in metfor-
min effects appears to be the modulation of membrane hyperpolari-
zation. The substantial decrease of the ACh-induced relaxation after
perfusion of the mesenteric arteriolar bed from MSG rats with TEA,
a K+ channel blocker, revealed the major participation of the hyper-
polarization for the vasodilator response, which could be a compen-
satory mechanism for the reduced NO production observed in this
model. The correction of this alteration might be suggested in our
study, since TEA was not able to decrease the ACh-induced response
in metformin-treated rats, similarly to that observed in control rats.
Accumulating evidences suggest that alterations in the produc-
tion/release of prostanoids by the endothelium directly contribute
to the endothelial dysfunction in vascular diseases (Yuhki et al.,
2010; Iñiguez et al., 2008). In fact, the increased vasoconstriction
and the reduced vasodilatation in MSG rats were corrected after
COX inhibition. Additionally, MSG rats displayed decreased PGI2/TX2
ratio in the mesenteric arteriolar bed. Therefore, the unbalanced
Fig. 3. Basal, norepinephrine- and acetylcholine-induced release of 6-keto-PGF-1α and
TXB2 from the mesenteric arteriolar bed perfusate of control, monosodium glutamate-
induced obese rats (MSG) and metformin-treated MSG rats (MSG-MET). * pb0.05 vs.
control. 6-keto-PGF-1α and TXB2 levels ratio are presented as the mean±S.E.M of
twelve independent experiments.
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might explain the endothelial dysfunction in MSG rats. Interestingly,
an important ﬁnding in this study was that the decreased PGI2/TXA2
ratio in MSG rats was not detected after metformin treatment, indi-
cating that metformin improves the endothelial function in MSG
rats by restoring the balance in the synthesis/release of prostanoids.Fig. 4. Nitric oxide (NO) production in mesenteric arteries from control, monosodium gluta
graphs show NO production measured by 4,5-diaminoﬂuorescein diacetate (DAF-2) ﬂuoresc
the absence/presence of L-NAME (100 μM), an NO synthase inhibitor, or BH4 (1 μM), an NO s
stimulated with ACh plus L-NAME. B — Representative ﬂuorographs of transverse sections w
is presented as the mean±S.E.M of six independent experiments. Scale bar: 20 μm.Although the accurate mechanisms involved in metformin effects
on the endothelium have not been elucidated, recent studies point
to the role of COX-2 (Matsumoto et al., 2008). In fact, we have dem-
onstrated that 16-week-old MSG rats displayed increased expression
of COX-2 that contributed to the increased contractile response to NE
as well as to the decreased relaxation in MSG rats (Lobato et al.,
2010). Considering that metformin corrected the decreased ratio
PGI2/TXA2 observed in the mesenteric arteriolar bed from MSG rats,
we suggest that metformin restored the COX-2-derived production
of prostanoids in this model of obesity.
The correction of the insulin resistance can also contribute to ex-
plain metformin effect on COX-derived vasoactive products, because
insulin resistance, increasing endothelial FFAs, can reduce arterial
prostacyclin synthase activity. FFAs commonly observed in insulin re-
sistant patients promote increased O2− production in endothelial cells,
by providing increased electron donors (NADH and FADH2) to the
mitochondrial electron transport chain. The FFA-induced overproduc-
tion of O2− activates a variety of proinﬂammatory signals and inacti-
vates two important enzymes, PGI2 synthase and eNOS (Du et al.,
2006; Kuboki et al., 2000), thus decreasing the endothelium-
dependent vascular relaxation.
Restoration of endothelium-derived factors release might not be
the only factor that accounted for metformin effect since SNP, which
acts via direct stimulation of vascular smooth muscle cells indepen-
dently of an intact endothelium, had its response increased by met-
formin treatment. SNP and NO, which is released by endothelial-
dependent vasodilators, share a ﬁnal common pathway to produce
vasodilatation, stimulating guanylate cyclase and increasing cGMP
levels. Thus, it is possible that a direct effect of metformin on vascularmate-induced obese rats (MSG) and metformin-treated MSG rats (MSG-MET). A — Bar
ence in basal condition and after stimulus with acetylcholine (ACh, 100 μM, 30 min) in
ynthase cofactor that enhances NO production. * pb0.05 vs. control. † pb0.05 vs. control
ith DAF-2 ﬂuorescence in basal condition. The mean optical density of the ﬂuorescence
Fig. 5. Reactive oxygen species generation in mesenteric arteries from control, monosodium glutamate-induced obese rats (MSG) and metformin-treated MSG rats (MSG-MET) in
the absence and presence of SOD (150 IU/mL),an O2− scavenger, or L-NAME (100 μM), an NO synthase inhibitor. A— Bar graphs show reactive oxygen species generation, measured
as hydroethidine-positive nuclei ﬂuorescence. * pb0.05 vs. control and MSG. # pb0.05 vs. MSG. B — Representative ﬂuorographs of transverse sections of mesenteric arteries with
hydroethidine-positive nuclei. The mean optical density of the ﬂuorescence is expressed as mean±SEM of six independent experiments. Scale bar: 20 μm.
234 N.S. Lobato et al. / Life Sciences 90 (2012) 228–235smooth muscle cells, improving the responsiveness to NO, could con-
tribute to the correction of the reduced vasodilatation in MSG rats. A
vasodilating effect of metformin has been reported in ex vivo prepa-
rations of vascular smooth muscle cells, possibly due to altered calci-
um handling (Dominguez et al., 1996; Abbasi et al., 1998). Therefore,
other mechanisms might be involved in the beneﬁcial effects of met-
formin on vascular function, as demonstrated in the present study.
One limitation of the present study was the use of an animal
model that may not necessarily reproduce the same pathophysiologic
abnormalities of human obesity. The cause of obesity in MSG rats is
not common among humans, although the phenotype parallels
human obesity in many ways. Other limitations of this study include
the short duration of metformin treatment, the use of only one vascu-
lar preparation (mesenteric arteriolar bed), that is not necessarily re-
ﬂective of other circulatory beds and the absence of experiments to
evaluate the direct action of this drug in the vessel. Thus, additional
studies are required to investigate metformin effects in other models
of obesity with additional time of treatment as well as in different
vascular beds, both in vivo and in vitro.Conclusion
In summary, the present study demonstrated that the metformin
treatment improved the vascular function in MSG rats through reduc-
tion in ROS generation, modulation of membrane hyperpolarization,
correction of the unbalanced prostanoids release and increase in the
sensitivity of the smooth muscle to NO. Our ﬁndings support the ben-
eﬁcial effects of metformin previously demonstrated in large inter-
vention studies in type 2 diabetic patients and also offer a credible
evidence for the beneﬁcial effects of this drug in obesity.Conﬂict of interest
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